Conference Call with Emcure Pharmaceuticals Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Pharmaceuticals company Emcure Pharmaceuticals announced Q3FY25 results Revenue: Rs 1,963 crore compared to Rs 1,668 crore during Q3FY24, change 17.7%. EBITDA: Rs 362 crore compared to Rs 294 crore during Q3FY24, change 23.2%. EBITDA Margins: 18.4% for Q3FY25. PAT: Rs 156 crore compared to Rs 120 crore during Q3FY24, change 30.3%. PAT margin: 8.0% for Q3FY25. Satish Mehta, CEO and Managing Director, Emcure Pharmaceuticals, said: “Emcure witnessed a strong performance in Q3. Our International business is seeing strong performance on back of our differentiated product portolio. On the domestic side, our focus is on expanding our covered market through differentiated product launches and driving synergies from the in-licensed Sanofi portolio. Moving forward, we aim to enhance our organic growth and margins through new product launches and operating efficiencies.” Result PDF